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Treatment for early-stage lung cancer: what next?
Lung cancer is the leading cause of cancer-related 
mortality worldwide, accounting for 19% of cancer-
related deaths.1 This devastating toll is the consequence 
of a high incidence (1·8 million new diagnoses in 
2012) and a low rate of cure. Most patients continue 
to be diagnosed at advanced disease stages. Moreover, 
the outcome of patients who present with resectable 
and operable lung cancer (about 25% of cases) is 
substantially worse than that noted in many other early-
stage solid tumours, with most patients eventually 
developing systemic relapse.
Based on the ability of systemic chemotherapy to 
improve outcome in advanced non-small-cell lung 
cancer (NSCLC), treatment strategies complementary 
to radical surgery, including adjuvant and neoadjuvant 
cytotoxic treatment, have been extensively studied. 
Indeed, postoperative chemotherapy has been 
consistently shown to prevent recurrences and 
increase survival in many clinical trials. The most recent 
publication of the NSCLC Meta-analysis Collaborative 
Group, based on 34 trials and 8447 patients, showed an 
absolute survival improvement at 5 years of 4% (hazard 
ratio [HR] 0·86, 0·81–0·92).2 Another meta-analysis 
that comprised ﬁ ve recent large trials (4584 patients), 
assessing cisplatin-based chemotherapy, estimated a 
5 year survival beneﬁ t of 5·4% for patients receiving 
adjuvant therapy compared with those that underwent 
surgery alone (0·89, 0·82–0·96).3 Consequently, 
adjuvant cisplatin-based chemotherapy has been 
widely adopted as the standard of care for patients with 
resected lung cancer. Evidence to support the use of 
adjuvant tegafur-uracil is mostly restricted to patients of 
east Asian origin with early-stage adenocarcinoma.4
In The Lancet, Sarah Burdett and colleagues5 
report a systematic review and individual patient 
data meta-analysis on the eﬀ ect of preoperative 
chemotherapy with subsequent surgery compared 
with surgery alone. The meta-analysis has been well 
conducted, included most randomised controlled 
trials (15) and patients (2385) treated in this context, 
and the results are scientiﬁ cally sound and relevant 
for routine clinical practice. This analysis formally 
conﬁ rms that neoadjuvant chemotherapy improves 
overall survival to a similar extent as adjuvant 
treatment (HR 0·87, 95% CI 0·78–0·96; or an increment 
in 5 year survival rate from 40% to 45%). This eﬀ ect was 
essentially due to a reduction in distant recurrence rate 
(0·69, 0·58–0·82), since no clear eﬀ ect on locoregional 
failure was evident (0·88, 0·73–1·07). Subgroup 
analysis suggested no diﬀ erential eﬀ ect on the basis 
of chemotherapy regimen used (number of drugs or 
treatment courses, platinum analogue employed), 
adjuvant radiotherapy received, or other patient and 
tumour characteristics. However, the robustness of 
these subanalyses is limited because some subsets of 
patients were scarcely represented (eg, stage IA or III).
This meta-analysis more deﬁ nitively substantiates the 
value of preoperative chemotherapy than individual trials 
or literature-based meta-analyses.6 Indirect comparisons 
with adjuvant studies suggest a similar eﬀ ect on survival 
(4–5% absolute gain at 5 years), although populations 
of patients might not be comparable because patients 
included in neoadjuvant trials probably had a higher risk 
of recurrence. Concordant with these data, three small 
studies that compared neoadjuvant with perioperative 
or postoperative chemotherapy in early-stage NSCLC 
showed similar outcomes for these diﬀ erent treatment 
strategies.7–9 Similarly, the sequence of local and systemic 
treatment does not seem to aﬀ ect cure rates in other 
disease settings such as osteosarcoma, or breast or 
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bladder cancer, although preoperative treatment spares 
the need for more radical and mutilating surgery in 
some patients.10 However, the rates of resectability or the 
need for pneumonectomy did not seem to improve with 
neoadjuvant treatment strategies in NSCLC patients.7–9 
One could speculate that this diﬀ erential outcome might 
be conditioned by the lower sensitivity of NSCLC to 
available systemic therapies.
Planned treatment delivery and dose intensity is 
consistently higher if chemotherapy is given pre-
operatively. Better tolerance and treatment adherence are 
relevant factors to consider when deciding the optimum 
timing of chemotherapy, particularly since systemic 
treatment does not increase early mortality rates after 
surgery. Based on these considerations, patients that 
are sure candidates for complementary chemotherapy, 
such as those with T3 (or T2 >4 cm) tumours or N1 
disease, might be the ideal candidates for a neoadjuvant 
approach, particularly if deﬁ nitive surgery is anticipated to 
be delayed.
Nevertheless, despite the beneﬁ t shown, only one 
of 13 patients with early-stage lung cancer actually 
beneﬁ ts from complementary chemotherapy, and at 
the expense of inducing relevant side-eﬀ ects in all 
treated patients. There is therefore an urgent need 
to develop predictive biomarkers to identify those 
patients who will proﬁ t from systemic treatment. 
In view of most recent results, it seems unlikely 
that a single gene or even more complex gene 
signatures will be ready for use in clinical practice in 
the near future, although some trials in progress are 
currently trying to address this issue. More probably, 
in our opinion, selected subgroups of patients 
with lung cancer with speciﬁ c genomic alterations 
(ie, tumours with activating EGFR mutations or 
ALK gene rearrangements) might derive larger beneﬁ ts 
from targeted therapies (ie, geﬁ tinib, erlotinib, or 
crizotinib) that have already been proven to aﬀ ect the 
natural history of advanced-stage disease.11,12 Indeed, 
speciﬁ c therapies directed against other oncogene-
driven solid tumours, with proven eﬀ ectiveness in 
the metastatic setting, have subsequently shown 
a substantial eﬀ ect in adjuvant or neoadjuvant 
settings.13 Studies testing such a hypothesis in NSCLC 
are ongoing, but available data so far are contradictory 
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Awareness is growing that tuberculosis is a major 
cause of disease and death in children from areas 
endemic with tuberculosis, but its contribution is 
poorly quantiﬁ ed because of diagnostic diﬃ  culties 
in resource-limited settings.1 Globally, in 2011, 
an estimated 1·3 million deaths in children were 
attributed to pneumonia.2 Most of these deaths 
occurred in areas endemic with tuberculosis, where 
the actual cause of death was rarely veriﬁ ed. Autopsy 
studies identiﬁ ed tuberculosis in 11% of children 
infected with HIV, and 8% of children not infected with 
HIV who died from respiratory disease in ﬁ ve African 
countries.3 Tuberculosis might also be an underlying 
cause of death in children dying from meningitis, 
sepsis, HIV/AIDS, or severe malnutrition, and its 
relative contribution to child morbidity and mortality 
is likely to increase if widespread rollout of Haemophilus 
inﬂ uenza type B, pneumococcal, and rotavirus vaccines 
reduces the eﬀ ect of these diseases.4
An emerging threat is the rise of drug-resistant 
tuberculosis, which poses a major challenge to global 
tuberculosis control eﬀ orts.5 WHO estimates that 
450 000 (range 300 000–600 000) cases of multidrug-
resistant tuberculosis (resistant to isoniazid and 
rifampicin) occurred in 2012, with less than 20% 
(77 000) of cases receiving appropriate treatment.6 
Failure to treat infectious multidrug-resistant 
tuberculosis cases facilitates ongoing transmission of 
drug-resistant strains and exposes vulnerable young 
children to infection.7 Crude projections estimate 
that roughly 10% of the global tuberculosis disease 
burden occurs in children,8 suggesting that around 
45 000 paediatric multidrug-resistant tuberculosis 
cases occurred in 2012. However, such estimates are 
diﬃ  cult to verify and fail to account for variability in the 
paediatric tuberculosis burden, which depends on the 
level of epidemic control achieved, the use of preventive 
therapy, and the population demographics in particular 
areas.9 In the absence of reliably reported data, accurate 
assessment of the paediatric disease burden requires 
evidence-based extrapolation from existing data and 
consideration of regional variation.
A study by Helen Jenkins and colleagues10 in 
The Lancet creatively combines three elements to 
estimate the number of incident tuberculosis and 
multidrug-resistant tuberculosis cases in children 
by WHO region. First, the authors did a systematic 
literature review to describe the relation between 
multidrug-resistant tuberculosis in children and 
treatment-naive adults, excluding studies in which 
children with drug-resistant tuberculosis were more 
likely to be included, such as outbreak and contact 
investigations. The proportions of multidrug-
resistant tuberculosis cases were similar (estimated 
slope of regression line 1·0691) in treatment-naive 
adults and in children with tuberculosis, showing 
that both groups represent local transmission of 
multidrug-resistant tuberculosis, consistent with 
previous observations.11 Country-level estimates of 
multidrug-resistant tuberculosis in treatment-naive 
adults then guided estimates of the proportion of 
child tuberculosis cases with multidrug-resistant 
tuberculosis, providing a neat solution to the absence 
of reliable data for multidrug-resistant tuberculosis in 
children.
Second, the authors adjusted sputum smear-positive 
cases reported to WHO by a factor that accounts for 
the expected age-speciﬁ c proportions of sputum 
smear-positive disease. Because some countries failed 
to report age-disaggregated data to WHO, Jenkins and 
colleagues ﬁ tted a logistic regression model with the 
estimated proportion of paediatric tuberculosis cases 
as the dependent variable and the log10 of the estimated 
tuberculosis incidence as the explanatory variable. The 
estimated percentage of tuberculosis cases in children 
aged younger than 15 years varied from 8% to 12%, 
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